PolTREG has been established as a spin-off from the Medical University of Gdańsk in order to develop and commercialize the patented TREG method.
PolTREG S.A. is the only entity authorized to implement the results of research in the field of the use of T-regulatory lymphocytes in the treatment of type 1 diabetes in children and the use of the method of their multiplication. The company’s mission is to make this breakthrough therapy available to the largest possible number of sick children in Poland and abroad.
The company was established in July 2015 after several months of preparatory work. At that time, a commercialization model and mechanisms for the legal protection of the invention were developed with the Gdańsk Medical University and the research team. The shareholders were:
– Centrum Innowacji Medycznych Sp. z o.o. – a special purpose company of the Medical University of Gdańsk, the creator of the TREG method and
– the deployment team, experienced in obtaining financing and managing innovative projects.
The first phase of the company’s activities was financially supported by business angels, and then INNOventure fund, which, using the funds of the Bridge Alfa Program and private investors, invested one million zlotys to initiate the registration process of TREG in the European Medicines Agency. In October 2015 the company received funding for the project entitled “Industrial production of TREGS lymphocytes as an advanced therapeutic product using a bioreactor” as part of the “Enterprise R&D projects” EU project. Thanks to the research on increasing the throughput of the TREG method it will be possible to use it on a wider scale in cooperation with the University Clinical Center in Gdańsk.
In 2015 and 2016, the company obtained funding for key areas of the project from:
– The National Centre for Research and Development, under the Intelligent Development Operational Program 1.1. for research on increasing the throughput of the TREG method;
– GO_GLOBAL program for working out the strategy of entering the American market, through cooperation with the acceleration program operating in Silicon Valley;
– Horizon 2020 for analytical work on further steps in the process of registration and commercialization of the method.
In June 2016, the company became a laureate of the first Polish edition of MIT Enterprise Forum Poland and took part in the second part of the acceleration program at the best technical university in the world – MIT in Boston (USA). The next step in the development of the company was the transformation of the limited liability company into a joint-stock company in 2016, in which the creators of the TREG method and the university (through its special purpose company) are still active.
In January 2017, the company obtained a loan from the Loan Fund for Supporting Innovation of the Polish Agency for Enterprise Development (Fundusz Pożyczkowy Wspierania Innowacji Polskiej Agencji Rozwoju Przedsiębiorczości), which will speed up the registration process and launch the company’s laboratory. In February 2017 Poltreg acquired new partners – investment funds Venture FIZ (TRIGON TFI) and PAAN Capital, which brought not only capital for further development of the company, but also knowledge and experience necessary for the success of this model commercialization, which will result in the registration of the first Polish original medicine in the European Medicines Agency.